Stocks in the NewsMost Active StocksPercent GainersPercent LosersFollowed Stocks
,

Latest News

Enviri Stock Up 120% as $43 Million Buy Makes It a Top Holding in This Portfoliofool.com
Enviri delivers environmental and specialty waste solutions for industrial clients through long-term contracts and value-added products.
Via The Motley Fool · February 22, 2026
Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decadesfool.com
The company might bend, but it won't break.
Via The Motley Fool · February 22, 2026
Urban Outfitters CCO Sells 18,666 Shares for $1.3 Millionfool.com
The Hayne family have been on a selling spree the last few months, but these transactions typically have one thing in common.
Via The Motley Fool · February 22, 2026
How Hose Length and Diameter Affect Pressure Drop in Airless Sprayerstalkmarkets.com
Via Talk Markets · February 22, 2026
If These People Aren't Buying, Why Are You?talkmarkets.com
Via Talk Markets · February 22, 2026
Boards Are Replacing CEOs At The Fastest Pace In Over A Decadetalkmarkets.com
Via Talk Markets · February 22, 2026
Top Picks 2026: Haverty Furnituretalkmarkets.com
Via Talk Markets · February 22, 2026
Integer Stock Down 38%, but One Fund Just Bet $40 Million on a Turnaroundfool.com
Integer Holdings supplies medical device components and finished products to major OEMs in cardiac, neuro, and surgical markets.
Via The Motley Fool · February 22, 2026
The Best Stocks to Invest $50,000 in Right Nowfool.com
Investors don't have to look any further than these two dominant internet firms.
Via The Motley Fool · February 22, 2026
Is Cognex Stock a Buy or Sell After a Director Dumped Shares Worth $128,000?fool.com
This automation technology leader, known for machine vision systems, reported a notable insider sale amid strong one-year share performance.
Via The Motley Fool · February 22, 2026
GoDaddy Inc. Implements More AI Features Ahead Of Earningstalkmarkets.com
Via Talk Markets · February 22, 2026
Counting on Home Equity to Fund Your Retirement? Here's Why You Shouldn't.fool.com
It might seem like a good plan, but it could backfire.
Via The Motley Fool · February 22, 2026
Prediction: 3 Stocks That'll Be Worth More Than Walmart 5 Years From Nowfool.com
Walmart has crushed the S&P 500 in recent years, but the red-hot stock is due for a cooldown.
Via The Motley Fool · February 22, 2026
Where Will Rocket Lab Stock Be in 10 Years?fool.com
The spaceflight company has shot up like, well, a rocket since its market debut a few years ago.
Via The Motley Fool · February 22, 2026
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decadesfool.com
Novartis has a solid portfolio of drugs and a pipeline that should keep the business humming.
Via The Motley Fool · February 22, 2026
JFrog's CTO Sold Shares Worth $2.5 Million. Is the Stock a Buy or Sell?fool.com
JFrog, a leader in DevOps software solutions, reported a notable insider sale amid ongoing growth in enterprise adoption.
Via The Motley Fool · February 22, 2026
Is CrowdStrike Stock a Buy After Falling 17% Year to Date?fool.com
CrowdStrike is still growing quickly, but the stock's valuation assumes that pace holds up with little noise.
Via The Motley Fool · February 22, 2026
Betting Against Wall Street: The Inverse ETF Surge No One Is Talking Aboutfool.com
The ProShares UltraShort Financials ETF ratchets up bearish bets on a popular sector.
Via The Motley Fool · February 22, 2026
2 Quantum Computing Stocks That Could Make a Millionairequantum-com
Quantum computing is still a high-risk frontier, but for patient investors, these two tickers could be tomorrow's generational wealth creators.
Via The Motley Fool · February 22, 2026
The Insider Report: Bulls Gasp for Air Following Tariff Rulingbenzinga.com
Via Benzinga · February 22, 2026
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Millionfool.com
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Via The Motley Fool · February 22, 2026
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Positionfool.com
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
Via The Motley Fool · February 22, 2026
2 Financial Stocks Poised for a Comeback in 2026fool.com
Both stocks are in the Berkshire Hathaway portfolio, selected by former CEO Warren Buffett.
Via The Motley Fool · February 22, 2026
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Convictionfool.com
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
Via The Motley Fool · February 22, 2026
Bill Gates' Daughter Wants Startup Phia to Stand Apart From Her Famous Last Namebenzinga.com
Via Benzinga · February 22, 2026